From this aspect, IDH-mutated gliomas might benefit from 2-HG’s epigenetic modifications for proliferation, whereas, gliomas with wild-type IDHs might turn to BCAA catabolism to sustain effective proliferation. The gene discussed is IDH1; the disease is central nervous system cancer.